ALXN Alexion Pharmaceuticals, Inc.

97.70
-0.80  -1%
Previous Close 98.50
Open 98.77
Price To book 2.49
Market Cap 21.94B
Shares 224,556,000
Volume 6,660,773
Short Ratio 1.71
Av. Daily Volume 2,462,380

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment to be completed in 2017.
Eculizumab
Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)
Phase 3 enrollment to be completed 2017; expects to initiate a Phase 3 trial in pediatric patients 2Q 2017.
ALXN1210
atypical Hemolytic Uremic Syndrome (aHUS)
Phase 2/3 enrolling.
ALXN1101
Molybdenum cofactor deficiency (MoCD) Type A
Phase 3 enrollment commenced 4Q 2016. Enrollment to be completed 2017.
ALXN1210
Paroxysmal nocturnal hemoglobinuria (PNH)
Phase 1/2 ongoing. No additional studies planned.
SBC-103
MPS IIIB
(sBLA) PDUFA date October 23, 2017.
Eculizumab
Refractory generalized myasthenia gravis (gMG)